Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials

Self-Identification Program

NCT06183359
Recruiting
Conditions Major Depressive Disorder, Third Wave Co...
Phase NA
Enrollment 86
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Conduct a pilot, single-center, randomized controlled 2-arm study aimed to evaluate the impact of an in-depth 3rd wave CBT program targeting correct self-identification (3rd level of 3rd wave CBT), compared to a control group receiving an acceptance and commitment therapy (ACT; (1st level of 3rd wave CBT, a well-known psychotherapy). Main judgment criteria : Therapeutic response (reduction ≥ 50% between pre and immediate post-treatment), and rate of relapse at 6 months post-therapy. Secondary objectives: Evaluate psychological processes involved in the reduction of moral pain, diligence, ruminations, suicidal ideas, self-concept and alterations in functioning (mental and social), psychological skills.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: SIP — compare the SIP group versus the ACT group

Primary Outcomes

  • Beck Depression Inventory (BDI) (Between pre- and immediate post-therapy, 3 months post-intervention and 6 months after the intervention (in the intervention group compared to the control group))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-27
Completion: 2028-02-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 86 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Montpellier
Contact Information
Study Contact:
Déborah Ducasse, MD
+33 4 67 33 28 29
d-ducasse@chu-montpellier.fr
Véronique Brand Arpon, IDE
v-arpon@chu-montpellier.fr
Interventions
  • Other: SIP — compare the SIP group versus the ACT group
Study Locations (1 sites)
CHU Montpellier, Montpellier, France
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 to 70 years, presenting a current major depressive episode (according to DSM 571), as part of unipolar or bipolar depressive disorder Exclusion Criteria: * Patients with a psychotic disorder * Patients with active thoughts of suicide with intention to carry out the act (C-SSRS "ideation suicidal" in the last week ≥ 4) * Inability to receive informed information about the study * Exclusion period determined by a previous study * Adult protected by law or patient under guardianship or curatorship * Not be affiliated to a French social security scheme or beneficiary of such a scheme * Not being able to give informed written consent * Pregnant or breastfeeding women * Patients under judicial protection
Conditions Breast Cancer
Phase NA
Enrollment 38
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized, controlled study is to test the effectiveness of digital technology-supported education on patients undergoing breast reconstruction after mastectomy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Other: digital technology-supported education — The education will include information about surgical process and care after surgery.

Primary Outcomes

  • Anxiety (Baseline and 30th days)
  • Surgical pain ((Change from baseline to 5th, 15th and 30th days will be assessed).)
  • Sleep quality ((Change from baseline to 5th, 15th and 30th days will be assessed).)
  • Quality of life after surgery ((Change from baseline to 5th, 15th and 30th days will be assessed).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-27
Completion: 2025-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 38 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Baskent University
Contact Information
Study Contact:
Aylin Günay, MSc,RN
+905330888921
aylingunay@baskent.edu.tr
Azize Karahan, Prof
+905324319456
kazize@baskent.edu.tr
Aylin Günay, MSc
90 312 246 6666/2138
aylingunay@baskent.edu.tr
Başkent University Hospital
Interventions
  • Other: digital technology-supported education — The education will include information about surgical process and care after surgery.
Study Locations (1 sites)
Başkent University Hospital, Ankara, Çankaya 06490 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Being diagnosed with stage 1, 2, or 3 breast cancer * Planned to undergo immediate breast reconstruction after mastectomy for the first time * Being between 18 to 75 years old * Able to use smart phone * Having smart phone with Android v5.0 or iOS v9.0 and above software, Bluetooth and internet connection * Having no hearing or visual impairment * Having no physical limitation * Turkish speaking volunteers Exclusion Criteria: * Patients planned to undergo total abdominal hysterectomy and bilateral salpingo oophorectomy with immediate reconstruction after mastectomy
Conditions Breast Cancer
Phase PHASE2
Enrollment 170
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to compare any good and bad effects of giving radiation treatment for breast cancer in 3 treatments over about 2 days.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Accelerated partial breast irradiation — High Dose Rate treatment delivery

Primary Outcomes

  • Assess the toxicity (at 1 and 3 years) of a 1.5-day APBI treatment course (1 year, and 5 years following irradiation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-12-12
Completion: 2033-01-31
Eligibility
Age: 45 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 170 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Virginia Commonwealth University
Principal Investigators:
  • Bridget Quinn, MD, Ph.D (PRINCIPAL_INVESTIGATOR) - Virginia Commonwealth University
Contact Information
Study Contact:
Massey IIT Research Operations
804-628-6430
masseyepd@vcu.edu
Massey CTO Breast Team
804-628-6430
masseyctbrst@vcu.edu
Virginia Commonwealth University
Bridget Quinn, MD, Ph.D
Virginia Commonwealth University
Interventions
  • Drug: Accelerated partial breast irradiation — High Dose Rate treatment delivery
Study Locations (1 sites)
Virginia Commonwealth University, Richmond, Virginia 23298 United States
Eligibility Criteria
Inclusion Criteria: * Female * New diagnosis of ductal carcinoma in situ (DCIS) and/or invasive breast carcinoma per histologic evaluation * Age 45-79 at diagnosis * Previous lumpectomy with surgical margins histologically free of invasive tumor and DCIS as determined by the pathologist. * T stage of Tis, T1, or T2. * T2 tumors must be ≤3 cm in maximum diameter * If the tumor is human epidermal growth factor receptor 2 (HER2)-positive, the patient must receive HER2-directed therapy. * For patients with invasive breast cancer, an axillary staging procedure must be performed (either sentinel node biopsy alone or axillary dissection \[with a minimum of 6 axillary nodes removed\]) and the axillary node\[s\] must be pathologically negative. * Note: N0(i+) is not an exclusion criterion. * Note: Patients meeting all of the following criteria are not required to undergo the axillary staging procedure: * ≥70 years of age * estrogen receptor, Her2 = human epidermal growth factor receptor 2, PR = progesterone receptor negative (ER+PR+HER2-) * G1-2 * Tumor ≤2 cm in size * Agrees to comply with aromatase inhibitor recommendation * Ability to understand and the willingness to sign a written informed consent document in English Exclusion Criteria: * Pregnant or breastfeeding * Active collagen-vascular disease * Paget's disease of the breast * History of DCIS or invasive breast cancer prior to the current diagnosis * Prior breast or thoracic radiation therapy (RT) for any condition * Multicentric carcinoma (DCIS or invasive) * Synchronous bilateral invasive or non-invasive breast cancer * Surgical margins that cannot be microscopically assessed or that are positive * Excision cavity that cannot be clearly delineated per the treating investigator * Any of the dosimetric treatment criteria defined in Section 6.1 have not been met. Patients who become ineligible due to inability to meet dosimetric criteria should not receive treatment as - defined in this protocol and will come off the study. Any subsequent adjuvant radiation will be delivered at the discretion of the treating physician * Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements
Conditions Breast Cancer
Phase Not Applicable
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this observational study is to investigate the significance of the HER2 receptor for brown fat activity in humans. Our preliminary data clearly demonstrates that the ErbB signaling pathway, which includes the HER2 receptor, strongly promotes development and function of cultured human BAT cells. The HER2 receptor is a part of the ErbB signaling pathway, and antibodies against thee HER2 receptor are a part of the standard treatment for HER2-positive breast cancer. Therefore, the hypothesis is that the activity of brown fat will be reduced in patients treated with HER2 blocking antibody compared to patients who are not treated with HER2 blocking antibody. The present study simply takes advantage of the treatment protocol to explore the contribution of the HER2 receptor in the development of brown adipose tissue in humans. Participants will complete two testing days, one before and one after their treatment period of approx. one year. On the testing days, identification of brown fat activity will be performed using cooling and infrared thermography. In addition, resting metabolic rate and a glucose tolerance test will be performed. Since presence of active brown adipose tissue in humans is inversely related to obesity, total and visceral fat mass, plasma glucose levels, presence of cardiovascular disease and diabetes status, it is of great importance to investigate the molecular mechanisms for development of brown fat tissue and may lead to discovery of novel strategies to counteract obesity and obesity related disorders.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Other: None (Observational study) — Both groups recieve standard care as decided by the responsible clinicians at the department of Oncology. The course of the treatment is completely independent from the observations in the present study.

Primary Outcomes

  • BAT activity (One year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-14
Completion: 2026-03-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rigshospitalet, Denmark
Principal Investigators:
  • Søren Nielsen, MSc., Ph.D. (PRINCIPAL_INVESTIGATOR) - Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Denmark
Contact Information
Study Contact:
Tora Ida Henriksen, MSc., Ph.D.
+45 35 45 73 78
tora.ida.henriksen@regionh.dk
Christina Yfanti, MSc, PhD
+45 35 45 76 26
christina.yfanti@regionh.dk
Tora Henriksen, PhD
+4535453545
tora.ida.henriksen@regionh.dk
Centre for Physical Activity Research (CFAS), Rigshospitalet, University of Copenhagen
Interventions
  • Other: None (Observational study) — Both groups recieve standard care as decided by the responsible clinicians at the department of Oncology. The course of the treatment is completely independent from the observations in the present study.
Study Locations (1 sites)
Centre for Physical Activity Research (CFAS), Rigshospitalet, University of Copenhagen, Copenhagen, 2100 Denmark
Eligibility Criteria
General inclusion criteria: * Female * Age \> 18 years * Histologically confirmed breast cancer * No prior neoadjuvant treatment * Estrogen receptor positive (\>1%) * Presence of cold activated brown fat as evidenced by a change in Δtemp. of \>1°C (post cooling - precooling temperature). HER2 positive group: HER2-positive (HER2+) and Estrogen receptor-positive (ER+) breast cancer patients (N = 15): * HER2 positive breast cancer as defined by ASCO/CAP criteria * Scheduled to receive adjuvant chemotherapy, a total of 17 series of trastuzumab and endocrine treatment Control group: HER2-negative breast cancer patients (HER2-) and Estrogen receptor-positive (ER+) breast cancer patients (N = 15): * HER2 negative breast cancer as defined by ASCO/CAP criteria * Scheduled to receive adjuvant chemotherapy and endocrine treatment Exclusion Criteria: * Any other cancer (excluding carcinoma in situ and radically operated localised squamous skin cancer) with clinical activity within the last 2 years * Metastatic breast cancer * Metabolic diseases such as diabetes (exceptions can be made if the disease is well treated, assessed by the clinically responsible medical doctor (see section 18)) * Regular use of prednisolone - use in relation to chemotherapy only is ok * Pregnancy * Untreated or dysregulated hypertension defined as outpatient clinic systolic BP \> 155 and diastolic BP \> 95 * Clinically significant ventricular or atrial arrhythmia * Untreated coronary artery disease or angina pectoris * Symptomatic heart failure (NYHA ≥ 2) * Known cold urticaria
Conditions Mental Health Literacy, Depression, Anxi...
Phase NA
Enrollment 1180
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study record describes a two-phase of clinical trial study. The first phase is a pilot study phase (to study feasibility and efficacy of the intervention), and the second phase is an effectiveness study phase (a fully powered evaluation study to test the intervention effectiveness). This proposal seeks to develop and test a new mHealth intervention, the mHealth Toolkit for Wellness \& Empowering Lives of School Community (mWEL) in Uganda. The mWEL-digial toolkit is a preventive intervention tool for teachers and parents as a self-help support modality. Caregivers who need support in navigating the toolkit will be supported by peer-community health workers (P-CHWs).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: mHealth Toolkit for Wellness & Empowering Lives of School Community (mWEL) — mWEL-App is a preventive intervention tool for teachers and parents as a self-help support. It integrates three key mental health presentive service functions: i) comprehensive screen to assess mental health (anxiety, depression), stress, and related contextual risks; ii) a tailored strength and weakness profile/report with recommendations to promote self-awareness and mental health knowledge; and iii) tailored evidence-based strategies and additional support and clinical resources to improve skills in stress management, emotion regulation, and maintain mental wellness. mWEL will be designed as a self-administered tool. Participating parents and teachers can access to mWEL app after they sign up for an account. Intervention participants will have access to the App anytime within a 3-5 month study period.

Primary Outcomes

  • Change in Universal Mental Health Literacy Scale Score (Baseline, Month 5)
  • Change in PHQ-9 Score (Baseline, Month 5)
  • Change in GAD-7 Anxiety Score (Baseline, Month 5)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-22
Completion: 2028-01-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Keng-Yen Huang, PhD, MPH (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
Keng-Yen Huang, PhD, MPH
646-501-2879
Keng-Yen.Huang@nyulangone.org
Demy Kamboukos, Ph.D.
646-754-4987
Demy.Kamboukos@nyulangone.org
Interventions
  • Behavioral: mHealth Toolkit for Wellness & Empowering Lives of School Community (mWEL) — mWEL-App is a preventive intervention tool for teachers and parents as a self-help support. It integrates three key mental health presentive service functions: i) comprehensive screen to assess mental health (anxiety, depression), stress, and related contextual risks; ii) a tailored strength and weakness profile/report with recommendations to promote self-awareness and mental health knowledge; and iii) tailored evidence-based strategies and additional support and clinical resources to improve skills in stress management, emotion regulation, and maintain mental wellness. mWEL will be designed as a self-administered tool. Participating parents and teachers can access to mWEL app after they sign up for an account. Intervention participants will have access to the App anytime within a 3-5 month study period.
Study Locations (2 sites)
Study Site, Kampala, Uganda
Study Site, Nakaseke, Uganda
Eligibility Criteria
Teachers Inclusion Criteria: * Teaching in recruited schools. * At least 18 years old. Parents Inclusion Criteria: * At least 18 years old. * Have a child aged 6-14 years. Exclusion Criteria: * Evidence of psychopathology or cognitive impairment severe enough to preclude giving consent, or completing the survey instruments or the focus group of the study. * Parents/Teachers/Caregivers who are not in one of our recruited primary school * Participants under the age of 18 * Participant who does not speak English and Luganda will not be able to participate
Conditions Arterial Hypertension, Blood Pressure, H...
Phase Not Applicable
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate whether in patients with initially poorly-controlled arterial hypertension, structural and functional differences in the retina and choroid remain after achieving a well-controlled blood pressure.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • Change in retinal vessel density after achieving blood pressure treatment target (OCT-A). (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-09-01
Completion: 2025-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Vienna
Contact Information
Study Contact:
Gerhard Garhöfer, Assoc. Prof. Priv. Doz. MD
01 40400 29880
klin-pharmakologie@meduniwien.ac.at
Gerhard Garhöfer, Assoc. Prof. PD MD
0043 1 40400 29880
gerhard.garhoefer@meduniwien.ac.at
Medical University of Vienna
Interventions
N/A
Study Locations (1 sites)
Medical University of Vienna, Vienna, 1090 Austria
Eligibility Criteria
Inclusion Criteria: * Men and Women aged ≥ 18 years * Signed informed consent * Apart from hypertensive retinopathy, normal ophthalmic findings * Non-Smokers * Patients with initially diagnosed or pre-existing mild to moderate primary arterial hypertension (systolic office blood pressure ≥ 140 mmHg and/or diastolic office blood pressure ≥ 90 mmHg) * Planned initiation of antihypertensive medication or planned adaption of antihypertensive medication by the Department of Cardiology * Subject agrees to perform regular blood pressure self-measurements and to document blood pressure values in a diary Exclusion Criteria: * Participation in a clinical trial in the three weeks preceding the study * Blood donation in the three weeks preceding the study * Symptoms of a clinically relevant illness in the three weeks preceding the study * History of family history of epilepsy * Secondary hypertension (e.g.: hyperaldosteronism, pheochromocytoma, renal artery stenosis, renal parenchymal diseases, Cushing-syndrome, Coarctatio aortae) * History of hypertensive encephalopathy or intracerebral bleeding * Diabetes mellitus Type 1 or Type 2 * Pregnant or breast-feeding women * Women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception
Conditions Type 2 Diabetes, PreDiabetes, Obesity, K...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

KDDP is a prospective, 12-month pilot study comparing the effects of a novel lifestyle program, the Ketogenic Diet and Diabetes Demonstration Project (KDDP) to those of the National Diabetes Prevention Program (NDDP). KDDP is modeled to mimic the delivery platform of NDPP with the exception that participants in KDDP will be placed on a medically-supervised ketogenic diet, and participants in NDPP will be placed on a low fat diet. The purpose of this study is to compare the metabolic effects of the KDDP and the NDPP on glycemic control, lipid parameters, blood pressure, heart rate, weight, and coronary artery calcium scores in individuals with either type 2 diabetes or prediabetes.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Ketogenic diet — KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
  • Behavioral: Low Fat diet — KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.

Primary Outcomes

  • Weight in kg (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-05
Completion: 2026-10-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of New Mexico
Principal Investigators:
  • Kristen Gonzales, MD (PRINCIPAL_INVESTIGATOR) - University of New Mexico
Contact Information
Study Contact:
Kristen M Gonzales, MD
505-272-3840
KrGonzales@salud.unm.edu
Matthew Bouchonville, MD
505-272-3840
mbouchonville@salud.unm.edu
Kristen Gonzales, MD
505-272-3840
KrGonzales@salud.unm.edu
University of New Mexico
Interventions
  • Behavioral: Ketogenic diet — KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
  • Behavioral: Low Fat diet — KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
Study Locations (1 sites)
University of New Mexico, Albuquerque, New Mexico 87131 United States
Eligibility Criteria
Inclusion Criteria: * Men and women ≥ 18 years old * BMI ≥27 kg/m2 * Hemoglobin A1c ≥ 5.7% and/or fasting plasma glucose of 100-125 mg/dL Exclusion Criteria: * Known clinical cardiovascular disease (i.e. prior stroke, myocardial infarction, peripheral artery disease) * LDL cholesterol ≥ 190 mg/dL * Triglycerides ≥ 500 mg/dL * History of type 1 diabetes * History of diabetic ketoacidosis * Individuals requiring insulin * Advanced renal disease * Advanced liver disease * Terminal cancer * Pregnancy
Conditions Colorectal Cancer, Breast Carcinoma, Sar...
Phase PHASE1
Enrollment 89
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This trial is a first in human (FIH) clinical trial in patients with Colorectal cancer (CRC) after failure of at least three lines of previous therapy aiming to evaluate safety and efficacy of CC-3, a bispecific antibody (bsAb) with CD276xCD3 specificity developed within DKTK. CC-3 binds to CD276 on cancer cells as well as to tumor vessels of CRC, thereby allowing for a dual mode of anti-cancer action. CC-3 was developed in a novel format which not only prolongs serum half-life, but most importantly reduces off-target T cell activation with expected fewer side effects. A similar construct in this format with PSMAxCD3 specificity is presently undergoing clinical evaluation in patients with prostate cancer (NCT04104607), with very favorable safety and preliminary efficacy. The optimized format that CC-3 shares with its PSMAxCD3 "sister molecule" allows for application of effective bsAb doses with expected high anticancer activity. The clinical trial comprises two phases: The first phase is a dose-escalation part to evaluate the maximally tolerated dose (MTD) of CC-3. This is followed by a dose-expansion part to defined the recommended phase II dose. A translational research program comprising, among others, analysis of CC-3 half-life and the induced immune response will serve to better define the mode of action of CC-3.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Administration of CC-3 — Accelerated titration phase, Standard 3+3 titration phase, expansion phase

Primary Outcomes

  • Safety 1-Adverse Events Assessment (Day 1 Day 2 Day 3 Day 8 +/- 1 day Day 9 Day 15 +/- 1 day Every 7 days +/- 2 days after Treatment week 3 7 days +/- 2 days after last CC-3 28 days +/- 2 days after last CC-3 28 days after FU +/- 3 days)
  • Safety 2 -Blood Chemistry-Transaminases (Day 1 Day 2 Day 3 Day 8 +/- 1 day Day 9 Day 15 +/- 1 day Every 7 days +/- 2 days after Treatment week 3 7 days +/- 2 days after last CC-3 28 days +/- 2 days after last CC-3 28 days after FU +/- 3 days)
  • Safety 3-Hematology-haemoglobin (Day 1 Day 2 Day 3 Day 8 +/- 1 day Day 9 Day 15 +/- 1 day Every 7 days +/- 2 days after Treatment week 3 7 days +/- 2 days after last CC-3 28 days +/- 2 days after last CC-3 28 days after FU +/- 3 days)
  • Safety 3-Hematology-Red Blood Cells (Day 1 Day 2 Day 3 Day 8 +/- 1 day Day 9 Day 15 +/- 1 day Every 7 days +/- 2 days after Treatment week 3 7 days +/- 2 days after last CC-3 28 days +/- 2 days after last CC-3 28 days after FU +/- 3 days)
  • Safety 3-Hematology-thrombocytes (Day 1 Day 2 Day 3 Day 8 +/- 1 day Day 9 Day 15 +/- 1 day Every 7 days +/- 2 days after Treatment week 3 7 days +/- 2 days after last CC-3 28 days +/- 2 days after last CC-3 28 days after FU +/- 3 days)
  • Safety 3-Hematology-White Blood Cells (Day 1 Day 2 Day 3 Day 8 +/- 1 day Day 9 Day 15 +/- 1 day Every 7 days +/- 2 days after Treatment week 3 7 days +/- 2 days after last CC-3 28 days +/- 2 days after last CC-3 28 days after FU +/- 3 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-01-12
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 89 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: German Cancer Research Center
Contact Information
Study Contact:
Juliane Walz, Prof. Dr.
+49 7071 29
kketi@med.uni-tuebingen.de
Jonas Heitmann, Dr.
+49 7071 29
kketi@med.uni-tuebingen.de
Jonas Heitmann, PD Dr.med.
+49 7071 29
kketi@med.uni-tuebingen.de
University Hospital Tuebingen
Interventions
  • Drug: Administration of CC-3 — Accelerated titration phase, Standard 3+3 titration phase, expansion phase
Study Locations (1 sites)
University Hospital Tuebingen, Tübingen, Baden-Wurttemberg 72076 Germany
Eligibility Criteria
Inclusion Criteria: written signed informed consent * Patient is able to understand and comply with the protocol for the duration of the clinical trial including undergoing treatment and scheduled visits and examinations * Patients with progressing metastatic CRC who were previously treated with FOLFOX, FOLFIRI, FOLFOXIRI, TAS-102, or regorafenib, if applicable in combination with anti-VEGFR monoclonal antibody (mAb) and anti-EGFR mAb (the latter, if RAS-wild-type and left sided tumors). In case of MSI-high/dMMR tumors, patients should have received checkpoint inhibitor therapy and at least two further lines of therapy of that stated above. In case of patients BRAF V600E mutation patients should have received: Cetuximab in combination with encorafenib in second- or third-line treatment. * At least one measurable lesion that can be accurately assessed at baseline by CT or MRI and is suitable for repeated assessment per RECIST 1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2 * Patient aged ≥ 18, no upper limit * Female patients of child bearing potential (FCBP) and male patients with partners of child bearing potential, who are sexually active, must agree to the use of two effective forms (at least one highly effective method) of contraception. This should be started from the signing of the informed consent and continue throughout period of taking study treatment and for 2 months after last dose of study drug. * For FCBP two negative pregnancy test (sensitivity of at least 25 mU/ml) prior to first application of CC-3 * All subjects must agree to refrain from donating blood while on study drug and for 2 months after last dose of CC-3. * Adequate bone marrow, renal, and hepatic function defined by laboratory tests within 14 days prior to study treatment: * Hemoglobin ≥ 9 g/dl (Transfusion of packed red blood cells prior to enrolment allowed) * Neutrophil count ≥ 1,500/mm3 * Platelet count ≥ 75,000/µl * Serum creatinine ≤ 1.5mg/dl or creatinine clearance ≥ 60ml/min * hepatic function of patients without current hepatic metastasis: * Bilirubin ≤ 1.5x upper limit of normal (ULN), in case of known Gilbert syndrome higher values are allowed if due to increase of indirect bilirubin * ALT and AST ≤ 2.5 x ULN * hepatic function of patients with current hepatic metastasis: * Bilirubin ≤ 2.5 x upper limit of normal (ULN) * ALT and AST ≤ 5. x ULN Exclusion Criteria: * Other malignancy requiring treatment within the last year except: adequately treated non-melanoma skin cancer and low-grade non-muscle invasive papillary bladder cancer. * Concurrent or previous treatment within 30 days in another interventional clinical trial with an investigational anticancer therapy * Persistent toxicity (≥ Grade 2 according to Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0) caused by previous cancer therapy, excluding alopecia and neurotoxicity * Clinical signs of active infection (\> grade 2 according to CTCAE version 5.0) * Known cerebral/meningeal manifestation of CRC * History of HIV infection * Viral active or chronic hepatitis (HBV or HCV) * Ongoing autoimmune disease * History of relevant CNS pathology or current relevant CNS pathology (e.g. seizure, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder) * Therapeutic anticoagulation therapy * Major surgery within 4 weeks of starting study treatment. Patients must have recovered from any effects of major surgery. * Patients receiving any systemic chemotherapy, mAb or radiotherapy within 2 (for mAb 4) weeks prior to study treatment or a longer period depending on the defined characteristics of the agents used * Heart failure NYHA III/IV * Severe obstructive or restrictive ventilation disorder * Known intolerance to CC-3 or other immunoglobulin drug products as well as hypersensitivity to any of the excipients present in CC-3 * Live and live-attenuated vaccination 30 days prior to treatment * Pregnant or breast-feeding women * Current ileus with severely altered GI function
Conditions TNBC - Triple-Negative Breast Cancer
Phase PHASE2
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a descriptive, prospective, single centre study. This study will assess PSMA expression via the uptake of radiolabelled PSMA-ligand using PET/CT imaging in mTNBC lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory mTNBC using the Lutetium-177 radiolabelled PSMA.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Ga-PSMA PET/CT — Patient undergo Ga-PSMA PET/CT prior to the start of the new drug treatment

Primary Outcomes

  • Assess PSMA expression in progressive metastatic TNBC patients (once at baseline prior to the start of the new anti cancer treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-05-30
Completion: 2025-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jules Bordet Institute
Contact Information
Study Contact:
Géraldine Gebhart, MD
025413095
geraldine.gebhart@hubruxelles.be
Loubna Taraji, Ms
025413781
loubna.taraji@hubruxelles.be
Loubna Taraji Schiltz
loubna.taraji@hubruxelles.be
Institut Jules Bordet
Interventions
  • Diagnostic Test: Ga-PSMA PET/CT — Patient undergo Ga-PSMA PET/CT prior to the start of the new drug treatment
Study Locations (1 sites)
Institut Jules Bordet, Brussels, Belgium
Eligibility Criteria
Inclusion Criteria: * Written informed consent in accordance with institutional guidelines and obtained prior to any study procedure * Women with ≥ 18 years-old * Eastern Cooperative Oncology Group Performance Status of 0 to 2 * Confirmed diagnosis of progressive metastatic TNBC and presenting measurable disease on 18F-FDG PET/CT (performed within 2 weeks) or Brain MRI in case of progressive brain metastases (performed within 4 weeks) prior to PSMA PET/CT. * Radiolabelled PSMA PET/CT has to be performed before the next treatment line initiation Exclusion Criteria: * Pregnant or lactating patients * Other active neoplastic disease * Treatment by another molecule that is the object of investigation within 30 days * Skin only metastatic disease * Patients with a significant medical, neuro-psychiatric, or surgical condition, which, in the investigator's opinion, may interfere with completion of the study
Conditions Breast Cancer Female
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective, single-center, observational clinical study, The objection was to observe the treatment of pyrotinib combined with trastuzumab and neoadjuvant chemotherapy Efficacy of Stage II-III breast cancer and observation of the efficacy of step-down neoadjuvant therapy for HER2-positive stage T1cN0M0 breast cancer.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pyrotinib and Trastuzumab — Small and large molecules combined with chemotherapy for neoadjuvant treatment of HER2-positive breast cancer

Primary Outcomes

  • tpCR (at surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-08-17
Completion: 2026-11-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Youzhi Zhu
Principal Investigators:
  • zhu youzhi (STUDY_CHAIR) - First Affiliated Hospital of Fujian Medical University
Contact Information
Study Contact:
zhu youzhi
17759120588
zhu@fjmu.edu.cn
youzhi zhu, master
The First Affiliated Hospital of Fujan Medical University
Interventions
  • Drug: Pyrotinib and Trastuzumab — Small and large molecules combined with chemotherapy for neoadjuvant treatment of HER2-positive breast cancer
Study Locations (1 sites)
The First Affiliated Hospital of Fujan Medical University, Fuzhou, Fujian China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged 18-75 years; 2. Her2-positive breast cancer confirmed by pathology; 3. invasive breast cancer confirmed by histology, Tumor stage: early stage (T1c-3, N0-1, M0) or locally advanced stage (T2-4, N2, N3, M0); 4. ECOG PS: 0-1 score; 5. Plan to undergo the final surgical removal of breast cancer, i.e. breast conserving surgery or total mastectomy, sentinel lymph node (SN) biopsy or axillary lymph node dissection (ALND) 6. Normal function of major organs means that the following criteria are met: (1) Blood test neutrophil (ANC) \>=1.5x10\^9/L; Platelet count (PLT) \>=90x10\^9/L; Hemoglobin (Hb) \>=90g/L; (2) Total bilirubin (TBIL) \<=1.5 upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<=1.5xULN; Alkaline phosphatase \<=2.5xULN; Urea nitrogen (BUN) and creatinine (Cr) \<=1.5xULN; (3) Left ventricular ejection fraction (LVEF) \>=55%; (4) The QT interval (QTcF) corrected by Fridericia method was less than 470msec in 12-lead ECG; 7. For women who have not undergone menopause or surgical sterilization: consent to abstinence or use an effective contraceptive method (during treatment and for at least 7 months after the last dose in the study treatment); 8. Volunteer to participate in this study, sign the informed consent, have good compliance and be willing to cooperate with follow-up. Exclusion Criteria: 1. Known allergic history of the drug components of this protocol; 2. Previous or co-existing other malignant tumors, except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix; 3. Participated in clinical trials of other antitumor drugs within four weeks; 4. Stage IV (metastatic) breast cancer; 5. Multiple factors affecting oral medication (e.g., inability to swallow, post-gastrointestinal resection, chronic diarrhea, and intestinal obstruction); 6. A history of congestive heart failure (CHF) or uncontrolled heart disease (angina, arrhythmia, hypertension); 7. Patients with active infection and severe mental illness; 8. Pregnant or lactating patients; 9. Patients with allergies or known history of allergies to the drug components of this protocol; A history of immunodeficiency, including being HIV positive, or having other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; 10. Concomitant diseases that, in the judgment of the investigator, seriously endanger the patient's safety or interfere with the patient's completion of the study.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In the current scenario, a reliable liquid biopsy method for predicting outcomes in solid tumors, especially among breast cancer patients, is lacking. Circulating Tumor Cells (CTCs) serve as crucial indicators of metastasis, and their early detection could significantly enhance patient stratification and facilitate the customization of personalized treatments. However, detecting CTCs in breast cancer patients presents complexities due to their substantial phenotypic heterogeneity and typically low concentration. Numerous approaches have been developed for CTC detection. Nonetheless, the currently available technologies remain intricate, time-consuming, and costly. The BioCellPhe Project is dedicated to the development of a novel device capable of isolating and characterizing individual CTCs. This innovative device relies on the identification of specific cell membrane proteins with remarkable precision, achieved through the application of novel orthogonal techniques. On one hand, engineered bacteria are utilized to precisely bind to membrane proteins of interest on CTCs. On the other hand, Surface Enhanced Raman Spectroscopy (SERS) is employed for the detection of individual molecules. Specifically, the BioCellPhe Project focuses on comprehensively studying CTCs in breast cancer patients, encompassing both metastatic and non-metastatic cases.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Device: Blood sample — For each patient, a 15 ml EDTA blood sample will be collected at different time-points

Primary Outcomes

  • Detect specific proteins on CTCs in breast cancer patients (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-12-01
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istituti Clinici Scientifici Maugeri SpA
Collaborators: Carlo Morasso
Contact Information
Study Contact:
Fabio Corsi, Professor
0382592272
fabio.corsi@icsmaugeri.it
Istituti Clinici Scientifici Maugeri SpA
Carlo Morasso, PhD
carlo.morasso@icsmaugeri.it
Istituti Clinici Scientifici Maugeri SpA
Interventions
  • Device: Blood sample — For each patient, a 15 ml EDTA blood sample will be collected at different time-points
Study Locations (1 sites)
Istituti Clinici Scientifici Maugeri SpA, Pavia, Lombardy 27100 Italy
Eligibility Criteria
Inclusion Criteria: * female patients with diagnosis of metastatic breast cancer, confirmed by clinical practice staging exams. * female patients with biopsy-confirmed diagnosis of early-breast cancer candidate for primary surgery after multidisciplinary evaluation. * patients not affected by any neoplastic disease. Exclusion Criteria: * Diagnosis of any neoplastic disease
Conditions Adverse Pregnancy Outcome
Phase PHASE2
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized clinical trial is to evaluate if we can use placental pathology in a prior pregnancy which had an adverse outcome, such as early delivery, stillbirth, a baby born smaller than expected, or severe forms of high blood pressure during pregnancy, to guide treatment in the subsequent pregnancy and reduce risk of recurrent adverse pregnancy events. The main questions it aims to answer are: * Whether enoxaparin prevents recurrent adverse pregnancy outcomes among patients with a prior adverse pregnancy outcome that occurred in the setting of maternal vascular malperfusion (MVM). * If enoxaparin reduces the occurrence or severity of MVM among patients with a prior adverse pregnancy outcome that occurred in the setting of MVM.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Lovenox 40mg — Enoxaparin is a blood thinner. It is approved for use in the prevention of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness; inpatient treatment of acute DVT with or without pulmonary embolism; outpatient treatment of acute DVT without pulmonary embolism; Prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction; treatment of acute ST-segment elevation myocardial infarction(STEMI) managed medically or with subsequent percutaneous coronary intervention. The use of Lovenox has been shown to be safe, and it has also been used widely off-label in pregnancy.

Primary Outcomes

  • Composite Adverse Pregnancy outcome (Enrollment through 6 weeks postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-12-26
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Endeavor Health
Principal Investigators:
  • Sunitha Suresh (PRINCIPAL_INVESTIGATOR) - Endeavor Health
Contact Information
Study Contact:
Sunitha Suresh
(847) 570-2860
SSuresh@northshore.org
Kate Honeyfield
847-570-2243
KHoneyfield@northshore.org
Sunitha Suresh, MD
NorthShore University HealthSystem
Interventions
  • Drug: Lovenox 40mg — Enoxaparin is a blood thinner. It is approved for use in the prevention of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness; inpatient treatment of acute DVT with or without pulmonary embolism; outpatient treatment of acute DVT without pulmonary embolism; Prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction; treatment of acute ST-segment elevation myocardial infarction(STEMI) managed medically or with subsequent percutaneous coronary intervention. The use of Lovenox has been shown to be safe, and it has also been used widely off-label in pregnancy.
Study Locations (1 sites)
NorthShore University HealthSystem, Evanston, Illinois 60201 United States
Eligibility Criteria
Eligibility Criteria: Inclusion (must meet all three criteria): 1. Subjects with a prior adverse outcome in a prior pregnancy. Adverse outcome is defined as prior singleton preterm birth ( \< 37 weeks), SGA infant (defined as birthweight \< 10th percentile), preeclampsia with severe features, or stillbirth (fetal demise after 20 weeks gestation), as certified by an obstetrician 2. Patients with maternal vascular malperfusion on pathology from pregnancy with prior adverse pregnancy outcome, as certified by a perinatal placental pathologist 3. Current singleton pregnancy at \<16 6/7 weeks gestational age. Exclusion Criteria: 1. Anticoagulation planned for current pregnancy (including warfarin, enoxaparin, heparin) 2. Known major fetal anomaly 3. Contraindication to enoxaparin: Specifically active major bleeding, known thrombocytopenia (platelets \<100), hypersensitivity to enoxaparin sodium, hypersensitivity to heparin or pork products, hypersensitivity to benzyl alcohol 4. Chronic kidney disease with eGFR\< 60 5. Known chronic liver disease with baseline AST/ALT \> 3 x upper limit of normal 6. Subjects with mechanical prosthetic heart valves